RxDoctor Payments Data

Brenda O'Shea, MD

Psychiatry · Valparaiso, INNPI 1538506522

Payments from drug & device makers

$3,289in general payments, 2019–2025

Across 191 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$959
  • Otsuka America Pharmaceutical, Inc.$431
  • Corium, LLC$279
  • Vanda Pharmaceuticals Inc.$275
  • Lundbeck LLC$272
  • Takeda Pharmaceuticals U.S.A., Inc.$182
  • plus $890 from 15 others

What the payments were for

  • Food & beverage$3,274100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,289 in reported general payments places this provider in the 80th percentile of 514 psychiatry providers in Indiana.

See all psychiatry providers in Indiana

Medicare billing

Part B allowed, 2024
$22,159
Medicare patients
82
Services billed
275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl91$144,337
Abilify MaintenaAripiprazole46$136,159
RexultiBrexpiprazole27$52,997
Invega SustennaPaliperidone Palmitate13$46,564
Aripiprazole174$25,653
TrintellixVortioxetine Hydrobromide36$20,452
Lurasidone Hcl50$8,190
Quetiapine Fumarate226$6,434
Paliperidone ErPaliperidone24$6,090
Bupropion XlBupropion Hcl194$4,648
Ziprasidone Hcl34$4,571
Chlorpromazine Hcl13$4,058
Eszopiclone46$4,021
Buspirone Hcl203$3,607
Divalproex Sodium ErDivalproex Sodium41$3,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$431$189,15673 claims
AbbVieVraylar$959$144,33791 claims
Johnson & JohnsonInvega Sustenna$46$46,56413 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$182$20,45236 claims
Almatica Pharma LLCSertraline Hcl$17$1,10199 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 514 psychiatry providers in Indiana.

Other psychiatry in Valparaiso

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →